Compare Garmin Ltd. (GRMN) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Johnson & Johnson — how do they compare? Garmin Ltd. trades at $241.87 (market cap $46.62B), while Johnson & Johnson trades at $250.9 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 12.8× Garmin Ltd.'s market cap, and Johnson & Johnson pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| GRMN | JNJ | |
|---|---|---|
Market Cap | $46.62B | $594.63B |
Sector | Technology | Health |
52-Week High | $267.52 | $267.24 |
52-Week Low | $187.10 | $162.98 |
Enterprise Value | $44.09B | $627.57B |
Dividend Yield | 1.74% | 2.17% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $247.96, up 2.72% on the day, with a neutral technical outlook and mixed earnings history including recent beats. Revenue growth is strong, reaching $7.25B in 2025, with robust profitability margins. Recent news highlights product innovations in aviation and marine electronics, supporting growth prospects. The stock is near its consensus price target of $281.50, indicating moderate upside potential from current levels.
The outlook for GRMN is cautiously optimistic, driven by solid fundamentals and innovation, but tempered by high valuation ratios and a majority hold rating from analysts. Key risks include competitive pressures and market volatility, while institutional sentiment remains mixed with limited insider activity noted.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
